ID   2C4 gamma2A/JAK2
AC   CVCL_C0D5
SY   Gamma2A Jak2; Gamma2A/JAK2
DR   cancercelllines; CVCL_C0D5
DR   CancerTools; 151681
DR   Wikidata; Q112926938
DR   Ximbio; 151681
RX   PubMed=9001223;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; 1639; CD2.
CC   Genetic integration: Method=Transfection; Gene=MGI; MGI:96629; Jak2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Transformant: ChEBI; CHEBI:132982; Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride; Acridine mutagen ICR 191).
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C0D4 ! 2C4 gamma2A
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-09-24; Version: 7
//
RX   PubMed=9001223; DOI=10.1128/mcb.17.2.695; PMCID=PMC231795;
RA   Kohlhuber F., Rogers N.C., Watling D., Feng J., Guschin D.Y.,
RA   Briscoe J., Witthuhn B.A., Kotenko S.V., Pestka S., Stark G.R.,
RA   Ihle J.N., Kerr I.M.;
RT   "A JAK1/JAK2 chimera can sustain alpha and gamma interferon
RT   responses.";
RL   Mol. Cell. Biol. 17:695-706(1997).
//